SUVRETTA CAPITAL MANAGEMENT, LLC 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-13 08:41 am Purchase |
2022-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
SUVRETTA CAPITAL MANAGEMENT, LLC | 255,055 9.990% |
152,215 (+148.01%) |
Filing |
| 2021-12-16 4:32 pm Purchase |
2021-12-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
SUVRETTA CAPITAL MANAGEMENT, LLC | 102,840 5.200% |
102,840 (New Position) |
Filing |